Cardiac Safety/TQT White Papers & Case Studies

  1. Considerations When Selecting A CRO For Phase I Clinical Studies
    6/17/2013

    Phase I clinical trials are an integral step in the drug development process. Specific factors can influence the timelines and success of these studies. This white paper addresses the critical success factors for Phase I clinical studies and provides guidance on the appropriate capabilities, expertise and experience to evaluate as a sponsor selects a CRO.

  2. Advances In Electronic Data Capture Of Medical Data
    5/7/2013

    Electronic Data Capture (EDC) refers to the collection of medical data for patients enrolled in clinical trials. The most common mechanism is for staff at the investigative site to enter the data into a web-based interface, and for staff at the sponsor company to monitor the data using the same interface but with different security permissions. By Keith Howells

  3. Phase II Primary Insomnia Program In Need Of Full-Service CRO Management
    12/6/2012

    Clinilabs, a contract research organization (CRO), was selected by an international drug discovery and development company to provide full-service CRO management of a phase II primary insomnia program.

  4. Imaging For Cadiovascular Trials
    8/9/2012

    ICON Medical Imaging’s role as a medical imaging and endpoint core laboratory is to help sponsors assess the effect of therapies by independent and rigorous assessment of clinical and imaging endpoints.

  5. Mecial Imaging: Cardiac Safety
    8/9/2012

    ICON Medical Imaging provides clients with fully integrated Cardiac Safety services. We offer focused expertise in Cardiology, industry leading on-line technology and network of Clinical experts. Our technology allows real-time access to clinical data and progress of the project.

  6. ICON Clinical Development Overview
    8/9/2012

    ICON is one of the world’s largest providers of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies.

  7. Drug Safety: Providing Strategies And Solutions To Help Sponsors
    8/7/2012

    At ICON, we have the expertise that spans the entire lifecycle of drug development. Our team of global safety experts is ideally positioned to design and implement comprehensive drug risk management programs and Phase IV safety surveillance programs.

  8. Leaders In Biomarker Research - Brochure
    8/6/2012

    Biomarkers of disease are assuming an ever increasing role in the discovery and development of drugs. ICON has long recognized their importance in phases of the development process and has built significant expertise in biomarker development and anaylsis.

  9. Early-Phase Metabolic Development Datasheet
    2/12/2012
    ICON’s consultancy services advise on clinical pharmacology study designs based on preclinical data – including potential use of surrogate markers and pharmacodynamic models, validation of those markers and models, clear objective setting and flexible protocol design.
  10. Clinical Pharmacology Datasheet
    2/12/2012

    The clinical pharmacology team at ICON Development Solutions (ICON) has extensive experience in the design, study conduct and interpretation of clinical pharmacology studies across all major therapeutic areas.